Kornimate/medical-research-clean huggingface dataset:
comparison of the efficacy of peloid therapy and paraffin treatment in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this study compares the effectiveness of peloid therapy and paraffin treatment in carpal tunnel syndrome. patients who have already received 2 weeks of peloid therapy or 15 sessions of paraffin treatment will be assessed. pain and symptom severity are assessed using the visual analog scale (vas) and boston carpal tunnel syndrome questionnaire (bctq). electrophysiological examinations will also be conducted at the same time points: baseline, 4 weeks post-treatment, and a 12-week follow-up.

our study will include 60 patients aged 18-65 who visited the outpatient clinics of beylikdüzü state hospital between january 1, 2024, and september 1, 2024, and were diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological examinations. these patients received either peloid or paraffin treatment. patients with symptoms persisting for a minimum of 3 months will be included in the study. in this study, pain levels will be evaluated using the visual analog scale (vas), and the type and severity of symptoms will be assessed with the boston carpal tunnel syndrome questionnaire (bctq). at our hospital, the standard paraffin treatment consists of 15 sessions, administered 5 days per week, while the peloid therapy consists of 10 sessions, also administered 5 days per week. the vas, bctq scores, and electrophysiological evaluations of the patients will be assessed at the 4th and 12th weeks post-treatment. electrophysiological parameters including median nerve distal motor latency (mmndl), median nerve distal sensory latency (mnsdl), sensory nerve conduction velocity (sncv), compound muscle action potential (cmap), and sensory nerve action potential (snap) will be recorded.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 65 years old. * patients diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological evaluations. * patients experiencing symptoms for a minimum of 3 months. exclusion criteria: * patients diagnosed with neuropathic conditions such as polyneuropathy, brachial plexopathy, or thoracic outlet syndrome. * patients with a history of previous injections or surgery for carpal tunnel syndrome.

Keywords: carpal tunnel syndrome median neuropathy median nerve peloid therapy mud therapy
helicobacter pylori infection occurrence in russia

Conditions: Helicobacter Pylori Infection

Summary: this study is planned to reveal the occurrence rate of h.pylori infection in ambulatory settings' patients in russia and to compare the occurrence rates in different years in treatment-naïve and previously treated subjects.


Eligibility criteria:
inclusion criteria: * willingness to participate (based on the signed informed consent form); * age older than 12 y.o. (for subjects younger than 18 y.o. written informed consent of a legal representative was obligatory); * availability of demographic data and medical history, including previous treatment for h.pylori infection for subjects of "treatment-naïve" group: * no previous treatment for h.pylori infection in the anamnesis; * at least 6 weeks after previous use of any antimicrobial agents for any reason; * at least 2 weeks' time frame free of use of proton pump inhibitors, other anti-secretory agents and bismuth preparations. for "previously treated" group of subjects: * infection caused by h.pylori established earlier and * not less than 6 weeks after the end of eradication therapy with at least 2 antibiotics and a proton pump inhibitor for at least 7 days, based on a patient's report exclusion criteria: * history of surgery on chest, stomach, gut (excluding appendectomy or laparoscopic cholecystectomy performed more than 6 month before the enrolment); * advanced stage of chronic obstructive pulmonary disease, * allergies to citruses, * pregnant and breastfeeding women.

Keywords: helicobacter pylori occurrence ambulatory settings prospective trial
evaluation of the precision of the microperimetry function of the spectral oct/slo

Conditions: Age-Related Macular Degeneration; Geographic Atrophy; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion; Central Serous Retinopathy; Pattern Dystrophy of Macula; Epiretinal Membrane; Macular Hole

Summary: to conduct a precision study to assess the microperimetry function of the spectral oct/slo. the study will assess variability across measurements taken by three different operator-device configuration across clinical sites, variability between subjects within a given operator-device configuration, and variability within a subject for a single operator-device configuration.


Eligibility criteria:
inclusion criteria: * subject must be 21 years of age or older. * subjects recruited to cohort 1 will have no known retinal disease except for refractive errors (-7.5 d to +7.5 diopters).subjects who are recruited to cohort 2 will have one or more of the following retinal pathologies: early and intermediate age-related macular degeneration, geographic atrophy, diabetic retinopathy (mild, moderate, severe), macular edema secondary to diabetes, retinal vein occlusion, central serous retinopathy, pattern dystrophy, epiretinal membrane or macular hole. * subjects who have signed an informed consent form. * subjects who can comply with the protocol. exclusion criteria: * subjects younger than 21 years of age. * subjects who cannot comply with the protocol. * subjects who cannot complete the simple test procedures * subjects who are not available to be testing 3 times during the day (morning, mid - day, and afternoon). * subjects with visual acuity worse than 20/100 (best corrected). * subjects with dense media opacities. * ocular surgery anticipated on the day of the study visit.
timing of inguinal hernia repair in premature infants

Conditions: Inguinal Hernia; Premature Birth of Newborn

Summary: the purpose of this study is to determine whether early (before nicu discharge) or late (55-60 weeks post-menstrual age) inguinal hernia repair is safer for premature infants who have an inguinal hernia.

this is a randomized clinical trial comparing early versus late repair in premature infants with an inguinal hernia (ih) to determine which approach may be safer. safety in this trial is defined as the freedom from significant adverse events, a reduction in hospital days during the study period, and normal neurodevelopmental testing at 2 years. costs of each treatment strategy are also important and are being evaluated.

Eligibility criteria:
inclusion criteria: * infant with estimated gestational age at birth of \< 37 weeks, 0 days * in a nicu at participating site * diagnosed with an ih per the pediatric surgery team * parents and providers willing to randomize the infant exclusion criteria: * infant is undergoing another operative procedure and ih repair is planned as a secondary procedure (e.g. fundoplication or g tube is planned, and ih repair is considered a secondary procedure) * known major congenital anomaly that impacts neurodevelopmental outcome or chromosomal abnormality * family unable to return for follow up and later ih repair; or likely unable to monitor ih as outpatient

Keywords: inguinal hernia premature infants anesthesia safety neurodevelopmental outcome preterm infants neonatal prematurity
calprotectin and ischemia modified albumin serum to measure disease activity in behçet's disease

Conditions: Behçet's Diseasecases

Summary: behçet's disease activity was evaluated using bd current activity form (bdcaf). serum calprotectin and ima concentrations were compared among active bd cases, inactive bd cases and control subjects.


Eligibility criteria:
inclusion criteria: * new case of behçet's disease available medical record well known duration of bd, well known current treatment used well known current organ involvement exclusion criteria: * concomitant autoimmune or auto-inflammatory disorder; acute or chronic infections; cancer; diabetes; heart failure; gestation or up to six months after birth
study on new strategies for hepatitis b virus immunization

Conditions: Vaccine Reaction

Summary: to investigate the immunogenicity of hb vaccine with different series among primary immune adults aged 25-55, to assess potential alternative approaches for hb immunization.

by comparing the immunization effect of hepatitis b vaccine with other different types of hepatitis b vaccines using seris procedure, information on the immunization effect of 60 micrograms of hepatitis b vaccine in adults was obtained, which will provide a scientific basis for the development of a rapid immunization procedure for adults with large doses of hepatitis b vaccine and for the improvement of the immunization strategy for hepatitis b in adults.

Eligibility criteria:
inclusion criteria: * aged 25-55 years * negative for hbsag,anti-hbs, and anti-hbc without prior hbv or hav vaccination exclusion criteria: * a history of vaccine component allergies * autoimmune diseases * immunodeficiency * vaccinations received within the past month * acute illnesses within the past week * fever (axillary temperature exceeding 38°c) within the past three days
non-eosinophilic neutrophilic asthma

Conditions: Neutrophilic Asthma

Summary: define and characterize the neutrophilic phenotype of severe asthma.

neutrophilic asthma (na) is the asthma phenotype less known, causes a severe disease and does not have a specific treatment. research on the neutrophilia mechanisms, new neutrophil (neu) types and bronchial microbiome, can provide an opportunity to better understand the na pathogenesis. objectives: 1. to describe the clinical characteristics of na and its sub-phenotypes (substudy 1); 2. to determine the neu types associated with the na and its sub-phenotypes (substudy 2); and 3. to identify the bronchial microbiological flora of the na, specifically related to lung microbiome and the immune response against chlamydia pneumoniae (substudy 3). methods: multicenter prospective study including 100 patients with severe asthma (gina/gema criteria): 50 with non-neutrophilic asthma (\ 64% neu in is). substudy 1: clinical variables (years of evolution, exacerbations, asthma control test, mini asthma quality of life questionnary), comorbidities (gerd, nasal polyposis, obesity, ass), pulmonary function (fev1, exhaled fraction of nitric oxide, total lung capacity, aspergillus), prick-test and ct scan chest; substudy 2 (in is and plasma): apoptotic index by means ne culture and flux cytometer (annexin-v-fitc), neu phenotype by surface markers (cd16, cd66b, cd62l, hladr, cd177, cd11b, cd63, cxcr2, cxcr4) with density gradient study and determination of cytokines (il-6, il-8, il-17, il-1, il-22) by elisa; substudy 3 (in is): bronchial microbiome for 16 subunit rrna by phylogenetic investigation of communities by reconstruction of unobserved states (picrust), and anti-chlamydia pneumoniae immunoglobuling a by elisa.

Eligibility criteria:
inclusion criteria: * 18 - 80 years old * confirmed diagnosis of asthma (according to spanish guideline gema) * severe persistent asthma (step 5-6 gema) * eosinophils\<300/mm3 in peripheral blood exclusion criteria: * respiratory infection during the previous month * significant lung pathology not attributable to asthma (bronchiectasis with reiff score\>3)

Keywords: severe asthma induced sputum asthma phenotypes neutrophilic inflammation microbiome
pre-flight titration of supplemental oxygen

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate if supplemental oxygen during air travel can be reliably titrated using a hypoxia-altitude simulation test (hast). also, the effect of oxygen supplementation given with the various oxygen equipment allowed for air travel is studied.

international guidelines recommend supplemental oxygen if pao2 \< 6.7 kpa (50 mmhg) during air travel. hypobaric chamber exposure is the ideal test but is not widely available. in clinical practice, the hast has been recommended as the preferable test for pre-flight evaluation, and is used with increasing frequency. the oxygen dose during air travel has been recommended titrated during hast. in the study, supplemental oxygen titration during hypobaric chamber exposure is compared to oxygen titration during hast, to evaluate if hast can be used with confidence to titrate the amount of supplemental oxygen needed during air travel.

Eligibility criteria:
inclusion criteria: * copd patients who have performed a hypoxia-altitude simulation test with a pao2 \< 6.7 kpa exclusion criteria: * exacerbation or pneumothorax within the previous six weeks * ltot * anemia * pulmonary disease other than copd * cerebrovascular or symptomatic cardiovascular disease * claustrophobia * inability to equalize pressure in the middle ear

Keywords: oxygen hypoxemia air travel
an exploratory clinical study on bortezomib for the treatment of refractory rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the goal of this prospective single-arm open-label trial is to learn about efficacy and safety of bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. the main questions it aims to answer are: * is bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis? * is bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis? participants will: * receive bortezomib 2 mg per week subcutaneously for twelve weeks in total. * follow-up at weeks 4, 12, and 24, while biosamples will be collected.


Eligibility criteria:
inclusion criteria: * age \&gt;18 years and \&lt;70 years; * absolute neutrophil count ≥1.0×10\^9/l, platelet count ≥100×10\^9/l, aspartate transaminase and total bilirubin within 3 times and 1.5 times the normal upper limit, respectively, and serum creatinine clearance \&gt;60 ml/min; * voluntarily sign an informed consent form. exclusion criteria: * individuals with concomitant autoimmune diseases; * presence of severe, poorly controlled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neuropsychiatric diseases, or laboratory abnormalities that the investigator deems an unacceptable risk for the participant\&#39;s involvement in the study; * history of malignant tumors (or clinical cure time less than 5 years); * subjects who are pregnant or lactating, or planning to become pregnant or start breastfeeding during the study period; * vaccination with live virus vaccines within the 4 weeks prior to study entry; * allergy to borussertib or mannitol; * participation in any other investigational drug trial in the 12 weeks before the start of this study medication; * presence of active hepatitis or a history of severe liver disease at screening: defined as a positive test for hepatitis b surface antigen (hbsag) or anti-hepatitis c virus antibodies (hcvab) (note: if the result of hepatitis b core antibody (hbcab) is positive and hbsag is negative, hepatitis b virus (hbv) dna testing will be performed. if hbv-dna is negative, the patient is eligible.); * active herpes zoster infection, or occurrence of a severe infection in the 12 weeks before the start of the study medication (defined as requiring intravenous antibiotics or hospitalization); * other situations that investigators deem unsuitable for inclusion.

Keywords: rheumatoid arthritis bortezomib difficult-to-treat rheumatoid arthritis refractory rheumatoid arthritis
freedom study: myfortic in kidney transplant patients

Conditions: Kidney Transplantation

Summary: the primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.


Eligibility criteria:
inclusion criteria: * males and females aged 18 to 75 years. * recipients of first, heart-beating cadaveric, living unrelated or living related non-hla identical donor kidney transplant, treated with simulect® and neoral® as primary immunosuppression. exclusion criteria: * second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ. * kidneys from non-heart beating donors or hla identical living related donors. * abo incompatibility against the donor.

Keywords: mpa kidney transplantation acute rejection kidney function
evaluate the efficacy and safety of vvz-149 injections for the treatment of post-operative pain following abdominoplasty

Conditions: Pain, Postoperative

Summary: the purpose of this phase 3 study is to evaluate the efficacy and safety of an analgesic drug candidate, vvz-149 injections for treating post-operative pain following abdominoplasty.


Eligibility criteria:
inclusion criteria: * men and women between 18-70 years old, inclusive. female subjects must meet additional criteria according to childbearing potential. * planning to undergo abdominoplasty * ability to provide written informed consent * ability to understand study procedures and communicate clearly with the investigator and staff * american society of anesthesiologists (asa) risk class of i to ii. exclusion criteria: * emergency or unplanned surgery * previous abdominoplasty * pre-existing condition causing preoperative pain around the site of surgery * women who are pregnant or breastfeeding * chronic pain diagnosis and ongoing or frequent use of pain medications
pleth variability index (pvi) as a measure of volume status during transcatheter mitral valve repair

Conditions: Mitral Regurgitation

Summary: transcatheter mitral valve repair in the form of mitraclip® is a safe and effective alternative to surgical mitral valve repair/replacement in patients with high operative morbidity and mortality risk. successful mitraclip application depends on intraprocedural quantification of mitral regurgitation and left atrial pressure (lap) monitoring. the pleth variability index (pvi) is a noninvasive, dynamic index based on analysis of the respiratory variations in the plethysmographic waveform recorded transcutaneously by the pulse oximeter. studies demonstrate that pvi is accurate in predicting fluid responsiveness in mechanically ventilated adult patients. in this study, we wish to measure pvi during tmvr and correlate with invasive indices such as left atrial pressure (lap) and stroke volume variation. our study hopes to provide a real-time non-invasive alternative to invasive indices to better guide fluid management and improve hemodynamics.


Eligibility criteria:
inclusion criteria: * male and female patients with mitral regurgitation undergoing transcatheter mitral valve repair(tmvr) with mitra-clip(r) at henry ford hospital - main campus. exclusion criteria: * mitraclip(r) procedure unsuccessful (defined as no clip deployment and/or procedural interruption due to complication), concomitant aortic regurgitation or stenosis of moderate or greater degree existed, patients with grade ii or above diastolic dysfunction on echocardiography, previous mitral valve intervention (either surgical or percutaneous), patients requiring continuous vasopressor infusions during the procedure, or patients in whom pvi monitoring was not performed due to technical issues, patients with atrial fibrillation, or preprocedure moderate or greater mitral stenosis

Keywords: transcatheter mitral valve repair pleth variability index mitraclip
open label, phase i zd6474 head and neck cancer study

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to determine the maximum tolerated dose of zd6474 given in combination with radiation or in combination with chemotherapy and radiation in patients with squamous cell carcinoma of the head and neck.


Eligibility criteria:
inclusion criteria: * stage iii-iv squamous cell carcinoma of the head and neck exclusion criteria: * no previous treatment for head and neck cancer, adequate cardiac function

Keywords: squamous cell carcinoma
submerged vs non-submerged guided bone regeneration simultaneous to implant placement.

Conditions: Guided Bone Regeneration; Dental Implant; Submerged Regeneration; Bone Atrophy

Summary: dental implants are worldwide recognized one of the best manners to replace lost or hopeless prognosis teeth. there are different variables that creates proper conditions for long-term prognosis of implant treatments. implant position and surrounding bone around them, have been described in scientific literature to be key factors in the longevity of those treatments. it has to be defined the \&amp;#34;critical bone thickness\&amp;#34; around implants. it basically means that implants has to be completely surrounded by bone, that will serve as protection. if the implants are not surrounded by bone, procedures as guided bone regeneration may be performed. those procedures can be executed before or simultaneously during the implant placement. in the standard procedure, the simultaneous guided bone regeneration during implant placement requires to leave the implant and the regeneration healing below the gingiva, needing a second surgery for accesing to those implants. in this randomized controlled trial the hypothesis is to discover if not submerging this regenerations may show the same results than submerged ones. for that, the objective is to study the different variables around these regeneration to evaluate the performance of non-submerged protocol.


Eligibility criteria:
inclusion criteria: * • men and women over 18 years old. * patients requiring single-unit implant restoration in any tooth site of the maxilla and mandible in between teeth. * anticipation of a peri-implant buccal osseous dehiscence by means of a ct imaging (cone-beam computed tomography, cbct) with a maximum vertical dimension height (vdh) of 50%. * presence of adjacent teeth. * presence of antagonist teeth. * minimum primary stability of 25ncm. * non-smokers or light smokers (\< 10 cigarettes per day). * absence of systemic diseases that could influence the outcome of the therapy (i.e., uncontrolled diabetes mellitus, osteoporosis, biphosphonate medication). * tooth extraction performed at least 4 months before implant placement. * good level of oral hygiene (plaque index \< 25%) (löe, 1967) * written informed consent signed. * keratinized mucosa of at least 2mm on the buccal and lingual of the implant. exclusion criteria: * implant surgery requiring sinus lift procedure. * previous bone augmentation at the implant site. * active periodontal disease. * acute infection at the rehabilitation site. * long-term non-steroidal anti-inflammatory drug therapy (3 months). * lactating females or currently pregnancy. * severe cognitive or psychiatric disorders. * unwillingness to return for follow-up examination.